Reviews in Medical Virology

Papers
(The H4-Index of Reviews in Medical Virology is 34. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Evolution of the SARS‐CoV‐2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission332
Covid‐19 vaccines and variants of concern: A review218
Clinical characteristics and outcomes of pregnant women with COVID‐19 and comparison with control patients: A systematic review and meta‐analysis173
Neutralising antibody escape of SARS‐CoV‐2 spike protein: Risk assessment for antibody‐based Covid‐19 therapeutics and vaccines135
An overview on the seven pathogenic human coronaviruses109
Loop‐mediated isothermal amplification (LAMP): An effective molecular point‐of‐care technique for the rapid diagnosis of coronavirus SARS‐CoV‐2103
Proposed subtypes of post‐COVID‐19 syndrome (or long‐COVID) and their respective potential therapies91
Sex‐based differences in severity and mortality in COVID‐1987
Present variants of concern and variants of interest of severe acute respiratory syndrome coronavirus 2: Their significant mutations in S‐glycoprotein, infectivity, re‐infectivity, immune escape and v73
Cardiac complications following mRNA COVID‐19 vaccines: A systematic review of case reports and case series69
Covid‐19 and oral diseases: Crosstalk, synergy or association?64
Global prevalence and genotype distribution of norovirus infection in children with gastroenteritis: A meta‐analysis on 6 years of research from 2015 to 202061
Quantifying the risk of SARS‐CoV‐2 reinfection over time58
How artificial intelligence may help the Covid‐19 pandemic: Pitfalls and lessons for the future58
Diagnostic accuracy of serological tests and kinetics of severe acute respiratory syndrome coronavirus 2 antibody: A systematic review and meta‐analysis57
Potential detrimental role of soluble ACE2 in severe COVID‐19 comorbid patients56
Influenza vaccines: Past, present, and future54
Immunity and inflammatory biomarkers in COVID‐19: A systematic review53
Potency of BNT162b2 and mRNA‐1273 vaccine‐induced neutralizing antibodies against severe acute respiratory syndrome‐CoV‐2 variants of concern: A systematic review of in vitro studies52
Inflammatory and vascular biomarkers in post‐COVID‐19 syndrome: A systematic review and meta‐analysis of over 20 biomarkers51
Efficacy and secondary infection risk of tocilizumab, sarilumab and anakinra in COVID‐19 patients: A systematic review and meta‐analysis50
Respiratory viral co‐infections in patients with COVID‐19 and associated outcomes: A systematic review and meta‐analysis50
Update on the omicron sub‐variants BA.4 and BA.549
Seroprevalence of anti‐SARS‐CoV‐2 antibodies in Africa: A systematic review and meta‐analysis48
Genetic polymorphisms of ACE1, ACE2, and TMPRSS2 associated with COVID‐19 severity: A systematic review with meta‐analysis48
C‐reactive protein as an effector molecule in Covid‐19 pathogenesis47
Oral manifestations of Covid‐19‐A literature review46
Long‐term side effects and lingering symptoms post COVID‐19 recovery42
Global and regional circulation trends of norovirus genotypes and recombinants, 1995–2019: A comprehensive review of sequences from public databases42
Classical and alternative receptors for SARS‐CoV‐2 therapeutic strategy42
Altered gut microbial metabolites could mediate the effects of risk factors in Covid‐1941
A systematic meta‐analysis of immune signatures in patients with COVID‐1939
ASSURED‐compliant point‐of‐care diagnostics for the detection of human viral infections36
Baseline physical activity is associated with reduced mortality and disease outcomes in COVID‐19: A systematic review and meta‐analysis36
Role of p38 mitogen‐activated protein kinase signalling in virus replication and potential for developing broad spectrum antiviral drugs34
Mesenchymal stem cells and their derived exosomes to combat Covid–1934
Recent insights into SARS‐CoV‐2 omicron variant34
Rhinovirus and asthma: Challenges and opportunities34
0.036837816238403